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Small Amounts of -Myosin Heavy Chain
Isoform Expression Significantly Increase
Power Output of Rat Cardiac
Myocyte Fragments
Todd J. Herron, Kerry S. McDonald
Myocardial performance is likely affected by the relative
expression of the two myosin heavy chain (MyHC) iso-
forms, namely -MyHC and -MyHC. The relative
expression of each isoform is regulated developmentally
and in pathophysiological states. Many pathophysiologi-
cal states are associated with small shifts in the relative
expression of each MyHC isoform, yet the functional
consequence of these shifts remains unclear. The purpose
of this study was to determine the functional effect of a
small shift in the relative expression of -MyHC. To this
end, power output was measured in rat cardiac myocyte
fragments that expressed 12% -MyHC and in myo-
cyte fragments that expressed 0% -MyHC, as deter-
mined in the same cells by SDS-PAGE analysis after
mechanical experiments. Myocyte fragments expressing
12% -MyHC developed 52% greater peak normal-
ized power output than myocyte fragments expressing
0% -MyHC. These results indicate that small
amounts of -MyHC expression significantly augment
myocyte power output.
Myocardial performance demonstrates plasticity throughprotein isoform switches.1 One cardiac protein, whose
isoform expression influences myocardial performance, is
myosin heavy chain (MyHC), the molecular motor that drives
myocardial contraction.2 Two functionally diverse MyHC
isoforms are expressed in mammalian myocardium, -MyHC
and -MyHC. The two MyHC isoforms display 93% amino
acid identity,3 yet -MyHC exhibits two to three times faster
actin-activated ATPase activity4 and actin filament sliding
velocity.5 Similarly, myocyte fragments that express exclu-
sively -MyHC generate nearly three times greater peak
normalized power than myocytes expressing only -MyHC.6
The relative expression of each MyHC isoform varies
throughout mammalian development7 and in pathophysiological
conditions such as hypothyroidism,7 diabetes,8 hypertension,4
and heart failure.9,10 In rodents, pathophysiological conditions
are associated with the downregulation of -MyHC and the
concomitant upregulation of -MyHC expression.4,7,8 Interest-
ingly, recent evidence has demonstrated a similar downregula-
tion of -MyHC protein expression and upregulation of
-MyHC expression in failing human hearts.9,10 These studies
have shown that normal adult human hearts express a small but
detectable amount of -MyHC protein, whereas failing human
hearts express exclusively -MyHC. The functional conse-
quence of such a small shift in MyHC isoform expression,
however, is unclear. Therefore, the purpose of this study was to
determine if a small amount of -MyHC protein expression is
sufficient to augment single cardiac myocyte function. To this
end, power output was measured in single myocyte fragments
that expressed small amounts of -MyHC and in fragments that
expressed 0% -MyHC (ie, 100% -MyHC). The relative
expression of -MyHC and -MyHC was determined for each
myocyte by SDS-PAGE analysis and silver staining after me-
chanical measurements, thereby providing a direct correlation
between relative MyHC isoform expression and myocyte frag-
ment function.
Materials and Methods
Experimental Animals
Male thyroidectomized Sprague-Dawley rats (160 to 220 g) were
obtained from Harlan (Madison, Wis). It has been demonstrated that
3 weeks after thyroidectomy, rat myocardium expresses exclusively
-MyHC, whereas the expression of other myofibrillar proteins
appears unaltered.6,11,12 To obtain myocytes that expressed small
amounts of -MyHC, thyroidectomized rats were killed 2 to 2.5
weeks after surgery. To obtain myocytes that expressed exclusively
-MyHC, thyroidectomized rats were killed 3 to 5 weeks after
surgery. The care and use of animals were in accordance with
guidelines established by the Animal Care and Use Committee of the
University of Missouri.
Cardiac Myocyte Preparation and
Functional Measurements
Single skinned cardiac myocyte fragments were obtained by me-
chanical disruption of hearts from rats as described previously.13
Dimensions of the myocyte fragment preparations are listed in Table
1. The solutions and protocol for force-velocity and power-load
measurements have been previously described.13 After mechanical
attachment, myocyte fragment preparations were transferred from
relaxing solution into maximal Ca2-activating solution (pCa 4.5).
Once steady-state isometric force was attained, a series of force
clamps was performed to determine isotonic shortening velocities.
Ca2-activated force remained similar throughout the series of load
clamps (force after the load clamps was 0.920.09 [meanSD] of
the force before load clamps).
SDS-PAGE and Silver Staining
After the mechanical measurements, the relative expression of each
MyHC isoform was determined using SDS-PAGE and silver staining
as previously described.6,12 Silver staining intensity was determined
to be linear over the range of 0.5 ng to at least 30 ng MyHC protein,
which is within the range expected when single-myocyte MyHC
isoform expression changes from 0% to 100% of either isoform.
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Data Analysis and Statistics
Myocyte preparation length traces, force-velocity curves, and power-
load curves were analyzed as previously described.13 Unpaired
Student t tests were used to determine differences among myocyte
fragment dimensions, force-velocity characteristics, and peak power
between myocytes expressing 12% -MyHC and 0% -MyHC.
P0.05 was chosen as indicating significance between groups. All
values are expressed as meanSD.
Results
The Figure shows representative length traces, force traces,
normalized force-velocity, and power-load curves, as well as
the corresponding silver-stained gels for a myocyte fragment
that expressed 12% -MyHC and a myocyte that expressed
0% -MyHC. The myocyte fragment that expressed 12%
-MyHC generated 65% greater peak normalized power
(0.046 versus 0.028 P/Po · ML/sec) than the myocyte frag-
ment that expressed only -MyHC.
Force-velocity and power-load data were collected from 6
myocyte fragments that expressed small amounts of -MyHC
(11.72.7%) and 6 myocyte fragments that expressed almost
exclusively -MyHC (0.71.6% -MyHC). Mechanical data
from these myocyte fragments are presented in Table 2. The
expression of 12% -MyHC yielded 52% greater peak
normalized power output (0.0410.006 versus 0.0270.007
P/Po · ML/sec). Force-velocity relationships for myocyte
fragments expressing12% -MyHC were also significantly
less curved (a/Po0.140.03 for 12% -MyHC versus
0.080.04 for 0% -MyHC), and therefore Fopt was 37%
greater (0.260.02 versus 0.190.04) in 12% -MyHC
myocyte fragments.
Discussion
Considerable evidence suggests that MyHC isoform expres-
sion is a primary determinant of myocardial perfor-
mance.2,6,11,12 The role of MyHC in determining myocardial
performance has been underscored by the large number of
mutations of the -MyHC gene that have been described in
patients afflicted by hypertrophic cardiomyopathy14 and di-
lated cardiomyopathy.15 More than 50 different mutations
have been reported, and most of them reside in the head or
motor region of the molecule, specifically in the nucleotide
and actin binding domains.14 Likewise, despite a high degree
of amino acid identity between -MyHC and -MyHC, there
seems to be important sites of difference within regions of the
rod, tail-hinge, lever arm, and head region.3,16 The structural
differences between the two molecules are manifested func-
tionally in the myocardium and have led to the hypothesis
that the relative expression of the two MyHC isoforms is
critical in determining the contractile performance of the
heart. The effect of a small amount of relative -MyHC
expression on myocardial function, however, has been elu-
sive. Our results demonstrate that low relative expression of
-MyHC (12%) is sufficient to augment skinned myocyte
fragment function and further support the hypothesis that the
Effects of small amounts of -MyHC expression on loaded shortening and power output in skinned rat myocyte fragments. A, Repre-
sentative length traces during force clamps of a myocyte fragment that expressed 12% -MyHC and a myocyte fragment that
expressed 0% -MyHC. B, Normalized force-velocity and power-load relationships obtained during maximal Ca2 activations of the
myocyte fragment that expressed 12% -MyHC () and the myocyte fragment that expressed 0% -MyHC (). The gel inset shows
the MyHC bands for these 2 myocyte fragments. Loaded shortening velocities were faster and power output was greater over most
relative loads in the 12% -MyHC myocyte fragment, with peak normalized power being 65% greater in the 12% -MyHC myo-
cyte fragment.
TABLE 1. Myocyte Fragment Dimensions and Force
Sarcomere Length, m
Maximal Ca2-Activated
Force, NLength, m Width, m pCa 9.0 pCa 4.5
12% -MyHC myocyte fragments (n6) 14128 193 2.230.06 2.210.05 7.212.1
0% -MyHC myocyte fragments (n6) 17656 265 2.240.04 2.210.02 9.993.9
Values are meanSD.
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relative expression of the two MyHCs is critical in determin-
ing the contractile performance of the myocardium.
The functional differences between myocytes expressing a
small amount of -MyHC and myocytes expressing only
-MyHC reported in the present study may be largely
attributed to differences in crossbridge cycling rates. It is well
established that -MyHC exhibits faster actin-activated AT-
Pase activity,4 faster rates of force development,11 and in-
creased unloaded shortening velocity.11 Further, single
skinned myocytes that express exclusively -MyHC generate
nearly three times greater peak normalized power than
myocytes expressing only -MyHC.6 We were interested in
whether limited (12% or less) expression of -MyHC
would affect cardiac myofibrillar power-generating capacity,
especially because recent studies have shown variations in
MyHC expression of this range between normal and failing
human hearts.9,10 Power output was greater at all relative
loads in myocytes expressing small amounts of -MyHC and
peak normalized power output increased 52%. Interest-
ingly, model simulations have also predicted that small
amounts of -MyHC will markedly accelerate the rate of
twitch force production.17 Taken together, these results imply
that expression of just small amounts of faster cycling
crossbridges (ie, -MyHC) will have significant functional
impact during contractions against loads that the myocardium
encounters in vivo. Because stroke volume is largely deter-
mined by the rate of loaded myocardial shortening, our results
suggest that small relative -MyHC expression is significant
to augment stroke volume. This may be important especially
in times of stress such as during exercise, which necessitates
cardiac reserve.
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TABLE 2. Force-Velocity and Power Output Characteristics
Absolute Peak
Power, W/mg
Normalized Peak
Power, P/Po · ML/sec a/Po Fopt
Vmax,
ML/sec
12% -MyHC myocyte fragments (n6) 1.120.35* 0.0410.006* 0.140.03* 0.260.02* 0.670.12
0% -MyHC myocyte fragments (n6) 0.600.22 0.0270.007 0.080.04 0.190.04 0.610.12
Values are meanSD. Po indicates isometric force; P, force during isotonic shortening; P/Po, relative load; and ML/sec, isotonic
shortening velocity in muscle lengths per second.
*P0.05; significant difference versus 0% -MyHC myocytes.
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